Vibha Jawa

发表

Universal immunogenicity validation and assessment during early biotherapeutic development to support a green laboratory.

Ami C Bautista, Lei Zhou, Vibha Jawa, 2013, Bioanalysis.

2018 White Paper on Recent Issues in Bioanalysis: focus on flow cytometry, gene therapy, cut points and key clarifications on BAV (Part 3 - LBA/cell-based assays: immunogenicity, biomarkers and PK assays).

Neil Henderson, Rong Zeng, Renuka Pillutla, 2018, Bioanalysis.

Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy

Vibha Jawa, Bernd Meibohm, B. Meibohm, 2012, The AAPS Journal.

T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation.

Vibha Jawa, Anne S De Groot, Eric Wakshull, 2013, Clinical immunology.

Impact of Anti-Drug Antibodies in Preclinical Pharmacokinetic Assessment

Mark Ma, Ami C Bautista, Vibha Jawa, 2013, The AAPS Journal.

Immunogenicity testing by electrochemiluminescent detection for antibodies directed against therapeutic human monoclonal antibodies.

Vibha Jawa, Michael Moxness, Eugen Koren, 2005, Clinical chemistry.

Evaluating Immunogenicity Risk Due to Host Cell Protein Impurities in Antibody-Based Biotherapeutics

Vibha Jawa, Marisa K Joubert, Meghana Deshpande, 2016, The AAPS Journal.

Impact of matrix-associated soluble factors on the specificity of the immunogenicity assessment.

Ami C Bautista, Vibha Jawa, Steven J Swanson, 2010, Bioanalysis.

Universal Immunoassay Applied During Early Development of Large Molecules to Understand Impact of Immunogenicity on Biotherapeutic Exposure

Vibha Jawa, Hossein Salimi-Moosavi, V. Jawa, 2012, The AAPS Journal.

Immunogenicity and PK/PD evaluation in biotherapeutic drug development: scientific considerations for bioanalytical methods and data analysis.

Mark Ma, Vibha Jawa, Yow-Ming C Wang, 2014, Bioanalysis.